GLP-1 Drugs Market Projected to Reach USD 132.79 Billion by 2035
News related to:Towards Healthcare · 3 min read
Ottawa, Oct. 09, 2026 /CourierPR/ -- The global GLP-1 drugs market is poised for significant growth, with projections indicating a compound annual growth rate (CAGR) of 9.63% from 2026 to 2035. By 2035, the market is expected to reach a value of USD 132.79 billion, up from USD 52.95 billion in 2025 and USD 58.05 billion in 2026. North America, which accounted for 64% of the global market in 2025, is expected to remain a dominant region, but the Asia Pacific region is projected to be the fastest-growing market.
Semaglutide, a key player in the market, accounted for 49% of the market share in 2025. Injectable products currently represent 83% of the market, but oral GLP-1 therapies are expected to record the fastest growth. This shift is driven by the launch of oral therapies, such as Novo Nordisk’s Wegovy pill, which crossed three million U.S. prescriptions in just over five months, with more than 80% of new prescriptions coming from people who were new to GLP-1 therapy. This indicates that oral delivery is not only shifting existing injectable users but also expanding the addressable treatment population.
The competitive landscape is simultaneously changing, with tirzepatide emerging as a fast-growing drug-type segment. Eli Lilly reported USD 9.9 billion in worldwide Mounjaro revenue in Q2 2026, up 91% year over year, while U.S. Zepbound revenue reached USD 4.9 billion, up 44%. Mounjaro's international revenue increased 172%, although lower realized prices partially offset volume growth.
The obesity/weight management segment is becoming a major growth engine, expected to grow faster than the broader GLP-1 market. In March 2026, the U.S. FDA approved Wegovy HD, a 7.2 mg semaglutide injection, adding a higher-dose option for chronic weight management. This approval illustrates how manufacturers are extending established molecules through dose optimization while simultaneously investing in new mechanisms.
Oral GLP-1s are changing the competitive equation, with oral therapies expected to be the fastest-growing route of administration. Structure Therapeutics reported Phase 2 data for oral aleniglipron, showing 16.3% placebo-adjusted mean weight loss at 44 weeks at the 180 mg dose, with Phase 3 initiation targeted for the second half of 2026. For manufacturers, this creates opportunities around oral formulation technologies, tablet manufacturing, API capacity, packaging, distribution, patient adherence, and differentiated pricing models.
Manufacturing capacity is becoming a competitive asset, with the scale of investment demonstrating that supply capability is becoming strategically important. The market's competitive structure is increasingly defined by two established leaders, expanding oral competition, and a broad pipeline of next-generation mechanisms. Novo Nordisk is extending semaglutide through Wegovy pill and higher-dose Wegovy HD while expanding manufacturing capacity for oral products. Its Q2 2026 data showed continued GLP-1 volume growth across geographies and a 58% GLP-1 volume share.
Eli Lilly is scaling Mounjaro and Zepbound while investing heavily in manufacturing and advancing retatrutide and oral Foundayo. Its Q2 Mounjaro revenue reached USD 9.9 billion, demonstrating the commercial strength of tirzepatide. Zealand Pharma and Roche are advancing petrelintide toward Phase 3 development through their collaboration, with initiation planned for the second half of 2026. These developments signal a shift toward multi-hormone mechanisms, differentiated tolerability, oral delivery, longer duration, and improved weight-loss efficacy.
The market's competitive structure is increasingly defined by two established leaders, expanding oral competition, and a broad pipeline of next-generation mechanisms. Novo Nordisk is extending semaglutide through Wegovy pill and higher-dose Wegovy HD while expanding manufacturing capacity for oral products. Its Q2 2026 data showed continued GLP-1 volume growth across geographies and a 58% GLP-1 volume share.
Eli Lilly is scaling Mounjaro and Zepbound while investing heavily in manufacturing and advancing retatrutide and oral Foundayo. Its Q2 Mounjaro revenue reached USD 9.9 billion, demonstrating the commercial strength of tirzepatide. Zealand Pharma and Roche are advancing petrelintide toward Phase 3 development through their collaboration, with initiation planned for the second half of 2026. These developments signal a shift toward multi-hormone mechanisms, differentiated tolerability, oral delivery, longer duration, and improved weight-loss efficacy.
The GLP-1 market is no longer being defined solely by diabetes treatment. Type 2 diabetes remains the largest indication, with a 58% share in 2025, but obesity and weight management are expected to be the fastest-growing indication segment. This is changing the commercial profile of GLP-1 medicines from chronic diabetes products into broader metabolic-health platforms.